Amide oxazole compound
Provided is an amide oxazole compound, in particular a compound, as represented by formula (IV), or a pharmaceutically acceptable salt thereof.
1 . A compound represented by formula (II-1), formula (II-2), formula (II-3) or formula (I), or a pharmaceutically acceptable salt thereof,
wherein,
R 1 is selected from the group consisting of H, F, Cl, Br, I, OH, CN, —NR a R b , CH 3 , —C(═O)—C 1-3 alkyl and C 1-3 alkoxy, and the C 1-3 alkyl and C 1-3 alkoxy are independently and optionally substituted with 1, 2 or 3 halogens;
R 4 is selected from the group consisting of H, F, Cl, Br, I, OH, CN, —NR a R b , C 1-3 alkyl and —C(═O)—C 1-3 alkyl, and the C 1-3 alkyl is optionally substituted with 1, 2 or 3 halogens;
or, R 1 and R 4 are attached to form pyrrolyl with the attached atoms;
R 2 is selected from the group consisting of
and the
are optionally substituted with one F;
R 3 is selected
from the group consisting of
E 1 is selected from the group consisting of NH, O and S;
R 5 and R 6 are independently selected from the group consisting of H, F, Cl, Br, I, OH, CN, —C(═O)—C 1-3 alkyl and C 1-3 alkyl, and the C 1-3 alkyl is optionally substituted with 1, 2 or 3 halogens;
m is 1 or 2;
n is 1 or 2;
R a is independently selected from the group consisting of H and C 1-3 alkyl; and
R b is independently selected from the group consisting of H, C 1-3 alkyl and —C(═O)—C 1-3 alkyl.
2 . A compound represented by the following formula or a pharmaceutically acceptable salt thereof, wherein the compound is selected from:
3 . A method for treating hematoma in a subject in need thereof, comprising: administering the compound or the pharmaceutically acceptable salt thereof as defined claim 1 to the subject.
4 . The method as defined in claim 3 , wherein the hematoma is a diffuse large B-cell lymphoma.